Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective upped by equities researchers at Truist Financial from $460.00 to $520.00 in a research report issued on Tuesday,Benzinga ...

Contract lifecycle management firm SpotDraft, which is backed by marquee investors such as Wipro founder-chairman Azim ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by Royal Bank of Canada from $402.00 to $407.00 in a research note issued to investors on Tuesday,Benzinga reports.

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

Vertex valuation multiples have reached unsustainable ... and the other half SMB. Roughly one-third of its market opportunity is in the U.S., and two-thirds overseas. Much of this addressable ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

In November, the company reported third-quarter product sales that rose 12% year over year to an annualized $11.1 billion. Journavx isn't the only recently approved treatment that Vertex has for sale.